# Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Source: https://onco.cc/trials/nct03915184/  
OnCo record `nct03915184` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Zevorcabtagene autoleucel in multiple myeloma, run by CARsgen Therapeutics Co., Ltd., active and no longer recruiting.

## Summary

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) is a phase 1/2 interventional study registered as NCT03915184 by CARsgen Therapeutics Co., Ltd., with 105 participants planned, started 2019-09-25 and due to reach its primary completion in 2024-12-31. Interventions recorded: zevor-cel. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03915184
- Phase: 1/2
- Setting: Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
- Sponsor: CARsgen Therapeutics Co., Ltd.
- Enrolled: 105

## Sources

- ClinicalTrials.gov NCT03915184: https://clinicaltrials.gov/study/NCT03915184

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Zevorcabtagene autoleucel](https://onco.cc/drugs/zevorcabtagene-autoleucel/)
- companies: [CARsgen Therapeutics](https://onco.cc/companies/carsgen/)

---
JSON: https://onco.cc/api/v1/entities/nct03915184.json